Status:
COMPLETED
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
Third Military Medical University
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cogn...
Eligibility Criteria
Inclusion
- Patients with Type 2 Diabetes Mellitus
Exclusion
- T2DM with acute diabetic complications;
- type 1 diabetes;
- other diseases affecting cognitive function (e.g., congenital dementia, brain trauma, epilepsy, severe hypoglycemic coma, cerebrovascular disease, ischemic heart disease, renal dysfunction);
- alcohol abuse, mental illness, and psychoactive substance abuse;
- history of thyroid disease;
- any surgical or medical conditions that could significantly influence the absorption, distribution, metabolism, or excretion of interventional drugs;
- unwillingness to provide informed consent.
Key Trial Info
Start Date :
January 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05360147
Start Date
January 20 2021
End Date
May 10 2021
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The third hospital affiliated to the Third Military Medical University
Chongqing, Chongqing Municipality, China, 400042